Advertisement


Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib

2024 ASCO Annual Meeting

Advertisement

Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual disease negativity vs isatuximab with lenalidomide and dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma (Abstract 7501).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The current standard of care for newly diagnosed multiple myeloma, non-transplant eligible, but non-frail, usually patients from, let's say 65 to 79, 80 years old, is a triplet-based regimen called C38 Immunotherapy first in class [inaudible] plus Lenalidomide and Dexamethasone based on a study named MAIA that was for registration. And I guess most of the country in the world now use that triplet-based combination as standard of care. It has replaced a previous one called [inaudible]. We wanted to improve on the results, the main results, the most interesting results of MAIA, meaning the MRD negative rate, 10 to -5 threshold that was at 31% approximately, and we wanted to improve as well the survival that is at median at approximately five years, 62 months. So we created this phase three study, randomized one-to-one, two arms; one arm MAIA-like, but using Isatuximab, the second-in-class immunotherapy targeting CD38. isatuximab, lenalidomide, dexamethasone in the control arm, 135 patients versus isatuximab, lenalidomide, dexamethasone plus bortezomib, a protease inhibitor, first in class that we know for years and we know is extremely efficacious in myeloma in the study arm, a quadruplet-based regimen; again, 135 patients. The primary endpoint was the MRD-negativity rate at 10 to minus five at 18 months. And I'm not going to go through the secondary endpoint, the regular safety, survival types of response and other MRD endpoints. The results of the study are that we have met primary endpoint. The rate of MRD-negativity, 10 to minus five in the control arm, ISAL index was 26% similar to MAIA. It was more than 50%, 53% in the study arm, in the quadruplet-based regimen, which not only a positive study, because it was calculated initially at 30%, and it is more than 50, but it is even more than a positive study. It is a clinically meaningful improvement in MRD-negativity rate, because more than half of the patients actually reach MRD-negativity at 10 to minus five, which is unprecedented in myeloma in that population, in non-transplant eligible patients. The survival cannot be shared yet because it is immature. All of the patient have reached 18 months, but it is too early to talk about survival. Yet the safety profile was as expected; it was of course good, manageable. The bortezomib in that study was given weekly, so we have a lot improve the risk of side effects related to bortezomib. However, I have to disclose a slight increase in neurotoxicity. But overall, it was a quadruped regimen with a very interesting balance risk-benefit, given the incredible activity and given the slight increase in neurotoxicity in terms of safety profile. And so we believe that isatuximab, bortezomib, lenalidomide, dexamethasone, quadruped based regimen is the new standard of care and probably should replace the triple-based regimen that we were using before.

Related Videos

Lung Cancer

Narjust Florez, MD, and David R. Spigel, MD, on Limited-Stage Small Cell Lung Cancer: Results From the ADRIATIC Study

Narjust Florez, MD, of Dana-Farber Cancer Institute, and David R. Spigel, MD, of Sarah Cannon Research Institute, discuss phase III findings showing that durvalumab as consolidation treatment after concurrent platinum-based chemoradiotherapy improved survival outcomes compared with placebo in patients with limited-stage small cell lung cancer. According to Dr. Spigel, these data support durvalumab as a new standard of care in this population (Abstract LBA5).

Skin Cancer

Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery

Axel Hauschild, MD, of Germany’s University of Kiel and University Hospital Schleswig-Holstein, discusses phase III study results on neoadjuvant intralesional daromun vs immediate surgery for patients with fully resectable, locally advanced melanoma (Abstract LBA9501).

Gynecologic Cancers

Don S. Dizon, MD, on Ovarian and Other Extrarenal Clear Cell Carcinomas: Update on Nivolumab and Ipilimumab

Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).

Breast Cancer

Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment

Pierfranco Conte, MD, of the University of Padua, discusses phase III findings from the A-BRAVE trial, which was designed to evaluate the efficacy of avelumab, an anti–PD-L1 antibody, as adjuvant treatment for patients with early-stage triple-negative breast cancer who are at high risk (LBA500).

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer harboring a KRAS G12C mutation who had previously received a platinum-based chemotherapy with anti–PD-(L)1 treatment.

Advertisement

Advertisement




Advertisement